Vital Signs The Analyst's Perspective - October 2015 Issue

USD 450.00

* Required Fields

USD 450.00


Be the first to review this product

This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.

Table of Contents

Vital Signs The Analyst's Perspective - October 2015 IssueVital Signs - October 2015 IssueOctober Issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.